Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2012, Article ID 236572, 8 pages
http://dx.doi.org/10.1155/2012/236572
Research Article

PGC-1α Induction in Pulmonary Arterial Hypertension

1Department of Molecular Medicine, Research Foundation of the University General Hospital of Valencia, 46014 Valencia, Spain
2Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias, 46014 Valencia, Spain
3Department of Pharmacology, University of Valencia, 46010 Valencia, Spain
4Division of Pneumology, University General Hospital of Valencia, 46014 Valencia, Spain
5Division of Pneumology, University General Hospital of La Fé, 46026 Valencia, Spain
6Division of Pneumology, University General Hospital of Alicante, 03010 Alicante, Spain

Received 4 May 2012; Revised 13 June 2012; Accepted 10 July 2012

Academic Editor: Remi Mounier

Copyright © 2012 Manuel Mata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Rich, D. R. Dantzker, S. M. Ayres et al., “Primary pulmonary hypertension. A national prospective study,” Annals of Internal Medicine, vol. 107, no. 2, pp. 216–223, 1987. View at Google Scholar
  2. V. V. McLaughlin, S. L. Archer, D. B. Badesch et al., “ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association,” Circulation, vol. 119, no. 16, pp. 2250–2294, 2009. View at Google Scholar
  3. N. Galiè, M. M. Hoeper, M. Humbert et al., “Guidelines for the diagnosis and treatment of pulmonary hypertension,” European Respiratory Journal, vol. 34, no. 6, pp. 1219–1263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. G. E. D'Alonzo, R. J. Barst, S. M. Ayres et al., “Survival in patients with primary pulmonary hypertension: results from a national prospective registry,” Annals of Internal Medicine, vol. 115, no. 5, pp. 343–349, 1991. View at Google Scholar · View at Scopus
  5. M. R. Bristow, W. Minobe, R. Rasmussen et al., “β-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms,” Journal of Clinical Investigation, vol. 89, no. 3, pp. 803–815, 1992. View at Google Scholar · View at Scopus
  6. K. T. B. Mouchaers, I. Schalij, A. M. G. Versteilen et al., “Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension,” American Journal of Physiology, vol. 297, no. 1, pp. H200–H207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. L. Des Tombe, B. J. Van Beek-Harmsen, M. B. E. Lee-De Groot, and W. J. Van Der Laarse, “Calibrated histochemistry applied to oxygen supply and demand in hypertrophied rat myocardium,” Microscopy Research and Technique, vol. 58, no. 5, pp. 412–420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Zong, J. D. Tune, and H. F. Downey, “Mechanisms of oxygen demand/supply balance in the right ventricle,” Experimental Biology and Medicine, vol. 230, no. 8, pp. 507–519, 2005. View at Google Scholar · View at Scopus
  9. M. Sano, T. Minamino, H. Toko et al., “p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload,” Nature, vol. 446, no. 7134, pp. 444–448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. N. F. Voelkel, R. A. Quaife, L. A. Leinwand et al., “Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure,” Circulation, vol. 114, no. 17, pp. 1883–1891, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Hoshikawa, S. Ono, S. Suzuki et al., “Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia,” Journal of Applied Physiology, vol. 90, no. 4, pp. 1299–1306, 2001. View at Google Scholar · View at Scopus
  12. J. Q. Liu, I. N. Zelko, E. M. Erbynn, J. S. K. Sham, and R. J. Folz, “Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox),” American Journal of Physiology, vol. 290, no. 1, pp. L2–L10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Lakshminrusimha, J. A. Russell, S. Wedgwood et al., “Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 12, pp. 1370–1377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. N. Ahmed, H. B. Suliman, R. J. Folz et al., “Extracellular superoxide dismutase protects lung development in hyperoxia-exposed newborn mice,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 3, pp. 400–405, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Elmedal, M. Y. de Dam, M. J. Mulvany, and U. Simonsen, “The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats,” British Journal of Pharmacology, vol. 141, no. 1, pp. 105–113, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Leopold, “Redox pioneer: Professor Joseph Loscalzo,” Antioxidants & Redox Signaling, vol. 13, no. 7, pp. 1125–1132, 2010. View at Google Scholar · View at Scopus
  17. Z. Wu, P. Puigserver, U. Andersson et al., “Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1,” Cell, vol. 98, no. 1, pp. 115–124, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Ding, X. Liang, D. Zhu, and Y. Lou, “Peroxisome proliferator-activated receptor α is involved in cardiomyocyte differentiation of murine embryonic stem cells in vitro,” Cell Biology International, vol. 31, no. 9, pp. 1002–1009, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Honda, K. Kaikita, K. Tsujita et al., “Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders,” Journal of Molecular and Cellular Cardiology, vol. 44, no. 5, pp. 915–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Shiomi, H. Tsutsui, S. Hayashidani et al., “Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction,” Circulation, vol. 106, no. 24, pp. 3126–3132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. T. L. Yue, J. Chen, W. Bao et al., “In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone,” Circulation, vol. 104, no. 21, pp. 2588–2594, 2001. View at Google Scholar · View at Scopus
  22. Ó. Fabregat-Andrés, A. Tierrez, M. Mata, J. Estornell-Erill, F. Ridocci-Soriano, and M. Monsalve, “Induction of PGC-1á expression can be detected in blood samples of patients with ST-segment elevation acute myocardial infarction,” PLoS ONE, vol. 6, no. 11, Article ID e26913, 2011. View at Google Scholar
  23. M. Mata, B. Sarriá, A. Buenestado, J. Cortijo, M. Cerdá, and E. J. Morcillo, “Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells,” Thorax, vol. 60, no. 2, pp. 144–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Casanova, B. R. Celli, P. Barria et al., “The 6-min walk distance in healthy subjects: reference standards from seven countries,” European Respiratory Journal, vol. 37, no. 1, pp. 150–156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. J. A. Calvo, T. G. Daniels, X. Wang et al., “Muscle-specific expression of PPARγ coactivator-1α improves exercise performance and increases peak oxygen uptake,” Journal of Applied Physiology, vol. 104, no. 5, pp. 1304–1312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Lin, H. Wu, P. T. Tarr et al., “Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres,” Nature, vol. 418, no. 6899, pp. 797–801, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Leick, J. Fentz, R. S. Biensø et al., “PGC-1α is required for AICAR-induced expression of GLUT4 and mitochondrial proteins in mouse skeletal muscle,” American Journal of Physiology, vol. 299, no. 3, pp. E456–E465, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Nozik-Grayck, H. B. Suliman, S. Majka et al., “Lung EC-SOD overexpression attenuates hypoxic induction of Egr-1 and chronic hypoxic pulmonary vascular remodeling,” American Journal of Physiology, vol. 295, no. 3, pp. L422–L430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. N. Ahmed, Y. Zhang, C. Codipilly et al., “Extracellular superoxide dismutase overexpression can reverse the course of hypoxia-induced pulmonary hypertension,” Molecular Medicine, vol. 18, no. 1, pp. 38–46, 2012. View at Publisher · View at Google Scholar
  30. F. A. Masri, S. A. A. Comhair, I. Dostanic-Larson et al., “Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension,” Clinical and Translational Science, vol. 1, no. 2, pp. 99–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Milara, E. Gabarda, G. Juan et al., “Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries,” European Respiratory Journal, vol. 39, no. 4, pp. 927–938, 2012. View at Google Scholar
  32. J. Milara, J. L. Ortiz, G. Juan et al., “Cigarette smoke exposure up-regulates endothelin receptor B in human pulmonary artery endothelial cells: molecular and functional consequences,” British Journal of Pharmacology, vol. 161, no. 7, pp. 1599–1615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Milara, G. Juan, J. L. Ortiz et al., “Cigarette smoke-induced pulmonary endothelial dysfunction is partially suppressed by sildenafil,” European Journal of Pharmaceutical Sciences, vol. 39, no. 5, pp. 363–372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Rudarakanchana, R. C. Trembath, and N. W. Morrell, “New insights into the pathogenesis and treatment of primary pulmonary hypertension,” Thorax, vol. 56, no. 11, pp. 888–890, 2001. View at Publisher · View at Google Scholar · View at Scopus